The Diabetic Retinopathy drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Diabetic Retinopathy (DR) is a major complication of diabetes, where damage to the retina is caused by micro-vascular damage to retinal vessels. If untreated, diabetic retinopathy leads to progressive vision loss and eventually blindness. The World Health Organization (WHO) estimates that the prevalence of diabetes in Kenya at 3.3% and predicts a rise to 4.5% by 2025. However, two-thirds of diabetics may be undiagnosed. DR has a negative impact on the quality of life. People with severe vision loss require additional health resources and endure reduced levels of physical, emotional and social well-being. Improved serum lipid and blood pressure control can also slow the progression of retinopathy, especially when initiated soon after the diagnosis of diabetes.
The market is majorly driven by the increasing prevalence of diabetes and complications arising due to poor glycaemic control like Diabetic Retinopathy in Kenya. It is estimated that one in every three people with diabetes develop diabetic retinopathy. A study in Kenya found a prevalence of 35.9%.
The country is experiencing a rise in diabetes owing to demographic, nutritional and social changes such as urbanization.
The Development of new and improved drugs and advancement of technologies is expected to propel growth in the diabetic retinopathy drug market.
Increasing initiatives by Government of Kenya by implementation of National Diabetes Strategy and releasing guidelines for screening and management of Diabetic Retinopathy. A Diabetes Education Programme has also been implemented for healthcare staff.
However, there is a high unmet need for DR services in the country, which highlights the need to strengthen health systems. The barriers are lack of referral and inadequate knowledge of diabetes eye health.